Beranda › Kanker Metastatik › Michigan › Detroit
Uji klinis Kanker Metastatik di Detroit, MI
24 studi untuk Kanker Metastatik mencari peserta di lokasi sekitar Detroit (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Menerima pesertaFase 2/3
- Henry Ford Cancer- Detroit, Detroit
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Menerima pesertaFase 3
- Research Site, Detroit
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Menerima pesertaFase 1/2
- Henry Ford Cancer Institute, Detroit
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Menerima pesertaFase 1
- Karmanos Cancer Institute, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Menerima pesertaFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Menerima pesertaFase 3
- Karmanos Cancer Institute, Detroit
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Menerima pesertaFase 3
- Karmanos Cancer Institute, Detroit
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Clinical Study Site, Detroit
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Menerima pesertaFase 2
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Menerima pesertaFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Menerima pesertaFase 1/2
- Crinetics Study Site, Detroit
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Menerima pesertaFase 1
- Henry Ford Hospital, Detroit
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- Investigative Site #120, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- Henry Ford Health System, Detroit
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Henry Ford Hospital, Detroit
Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases
Menerima peserta
- Henry Ford Hospital, Detroit
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Menerima pesertaFase 1/2
- Henry Ford Cancer Institute, Detroit
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Menerima pesertaFase 3
- Henry Ford Health System, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Menerima pesertaFase 1/2
- Karmanos Cancer Institute, Detroit
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Menerima pesertaFase 1/2
- Karmanos Cancer Institute, Detroit
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Menerima pesertaFase 1
- Henry Ford Cancer Center, Detroit
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Menerima pesertaFase 1
- Henry Ford Cancer Institute, Detroit
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Menerima pesertaFase 1
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
Menerima pesertaFase 1/2
- Karmanos Cancer Institute, Detroit
Uji klinis Kanker Metastatik di kota lain
- Houston, TX104 studi
- New York City, NY93 studi
- Nashville, TN70 studi
- Boston, MA63 studi
- Los Angeles, CA57 studi
- St. Louis, MO54 studi
- Arlington, VA53 studi
- Philadelphia, PA46 studi
- Chicago, IL45 studi
- San Antonio, TX44 studi
- Washington, DC43 studi
- Dallas, TX42 studi
Studi lain di Detroit
- Kanker Paru Non-Sel Kecil44 studi
- Kanker Payudara33 studi
- Kanker (semua jenis)29 studi
- Kanker Kolorektal26 studi
- Kanker Ovarium26 studi
- Kanker Prostat22 studi
- Kanker Endometrium21 studi
- Kanker Paru20 studi
- Mieloma Multipel19 studi
- Kanker Lambung16 studi
- Karsinoma Sel Skuamosa Kepala dan Leher15 studi
- Leukemia Mieloid Akut14 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.